Lentiviral FIX Gene Therapy

Key facts

Sponsor

Shenzhen Geno-Immune Medical Institute

Principal Investigator

Lung-Ji Chang, PhD

Shenzhen Geno-Immune Medical Institute

Intervention

YUVA-GT-F901(biological)

Enrollment

10 enrolled

Eligibility

2-65 years · All sexes

Timeline

2020 – 2022

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hemophilia B

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07285460
  A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
  Sanofi
• RECRUITINGPHASE3NCT07080905
  Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
  CSL Behring
• RECRUITINGPHASE1, PHASE2NCT06611436
  BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
  Be Biopharma
• ACTIVE NOT RECRUITINGPHASE3NCT06569108
  Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
  Suzhou Alphamab Co., Ltd.
• RECRUITINGPHASE3NCT06003387
  Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
  CSL Behring
• RECRUITINGNCT06008938
  An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B
  CSL Behring
• RECRUITINGNANCT05630651
  The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE1NCT05709288
  Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
  Institute of Hematology & Blood Diseases Hospital, China

See all trials for Hemophilia B →